12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
The unexpected emergence of the COVID-19 virus presents a wide range of new challenges and opportuni...
Read More >
A federal appeals court just ruled that workers don’t need to clear a heightened legal standard in ...
Read More >
Hot on the heels of the £20 million fine issued to British Airways, the Information Commissioner’s ...
Read More >
The recent Italian Tax Decree 2020 (Decree-Law no. 124 of 26 October, 2019, converted into Law no. 1...
Read More >
In this episode of Trekking Through Compliance, we consider the episode Day of the Dove which aired ...
Read More >
On November 20, 2019, the U.S. Department of Justice (DOJ) announced several subtle, but important, ...
Read More >